Do Inhaled Steroids Help Every COPD Patient? What Blood Eosinophils Predict

No. Inhaled corticosteroids do not help every person with COPD, and the job of the blood eosinophil count is to separate the patients likely to benefit from those who mostly carry the risk. The evidence points one way: the exacerbation-reducing effect of inhaled steroids climbs with the blood eosinophil count and shrinks toward negligible in people with very low counts. Global guidance now treats roughly 100 and 300 eosinophils per microliter of blood as practical dividing lines, read alongside a person's exacerbation history rather than in isolation. The number does not decide anything by itself, but it changes the odds that a steroid inhaler earns its place.

Where a blood test became a treatment signal

For years, inhaled steroids were handed out broadly in COPD, borrowed from asthma, where they are foundational. The signal that COPD is different came from looking back at trial data. A 2015 secondary analysis of two matched fluticasone furoate and vilanterol trials, led by Pascoe and colleagues in the Lancet Respiratory Medicine, reported that adding the steroid to a bronchodilator cut moderate and severe exacerbations by about 29 percent in patients whose eosinophils were at or above 2 percent of white cells, but by only about 10 percent, a difference that was not statistically significant, in those below that line. That was the first widely cited demonstration that a cheap, routine blood test might flag who responds.

Later work translated the percentage into absolute counts and tested the idea in other datasets. A post-hoc analysis of the WISDOM withdrawal trial found that patients who deteriorated after their inhaled steroid was removed clustered at counts of 300 cells per microliter or higher, and the later SUNSET study echoed the pattern. One caveat matters about the evidence grade here: most of these eosinophil findings are secondary or post-hoc analyses of trials designed to answer other questions, which is a good reason to treat the thresholds as pragmatic guides rather than hard biological switches.

What the GOLD thresholds actually mean

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report folds these numbers into a simple gradient. A count below 100 cells per microliter argues against starting an inhaled steroid, because benefit is unlikely. A count at or above 300 offers the strongest support, and the range in between signals an intermediate, increasing probability of benefit. A later analysis of the large IMPACT trial, again led by Pascoe, gave this gradient its clearest shape, reporting that the exacerbation benefit of steroid-containing regimens rose steadily with the eosinophil count, from minimal below roughly 100 cells to substantial above 300. Crucially, GOLD applies this only to people who keep having exacerbations despite bronchodilator therapy. Eosinophils modify the decision; they do not create the indication.

That distinction rests on an important limit of the biomarker. A pooled analysis of 22,125 patients across 11 trials, published by Singh and colleagues in Respiratory Research in 2020, found that a baseline eosinophil count is a weak predictor of who will exacerbate in the first place; a patient's own history of exacerbations does that job far better. So the count answers a narrow question, which is whether a steroid is likely to help this particular person, and not the broader question of who is destined to flare.

The pneumonia side of the ledger

The reason any of this matters is that inhaled steroids in COPD are not free. They raise the risk of pneumonia, an effect seen repeatedly and most strongly with fluticasone-based products. One proposed mechanism is that inhaled steroids blunt local airway defenses, including antimicrobial peptides such as cathelicidin, and may shift the airway microbiome toward bacterial dominance. Patients with low eosinophil counts already tend toward a more bacterial, neutrophilic airway, which is precisely the group that gains the least from the drug.

Put the two ledgers together and the logic of the threshold becomes clear. The excess pneumonia risk from inhaled steroids is not confined to the patients who benefit from them; patient-level analyses have found that people with low eosinophil counts, who gain the least, carry at least as much of the extra pneumonia burden. A person with very low eosinophils is therefore asked to accept a real infection risk in exchange for little expected gain. Formulation matters too, and pooled data have linked fluticasone to a higher pneumonia signal than budesonide. GOLD also lists repeated pneumonia and certain mycobacterial infections as separate reasons to steer away from inhaled steroids, independent of the eosinophil number.

Reading the number with humility

A single eosinophil count is a snapshot of something that moves. Values drift with time of day, infections, oral steroids, and season, and a person can cross a threshold between two blood draws. That variability is why guidance leans on repeated measurements when possible, and why a borderline count should not override a strong clinical story in either direction. The eosinophil count is a useful dial, not a verdict, and its best use is to make an already exacerbation-prone patient's steroid decision more rational than a one-size-fits-all reflex.

This article is educational and not medical advice; decisions about inhaled steroids belong in a conversation with a clinician who knows the whole picture.